Characteristics and occurrence of type 2 myocardial infarction in emergency department patients: A prospective study

, Adikari, Thushani, Mueller, Christian, Sandoval, Yader, Nestelberger, Thomas, , Hawkins, Tracey, & (2018) Characteristics and occurrence of type 2 myocardial infarction in emergency department patients: A prospective study. Emergency Medicine Journal, 35(3), pp. 169-175.

View at publisher

Description

Objective To identify differences in prevalence, demographics, clinical features and outcomes for type 1 myocardial infarction (T1MI) and type 2 myocardial infarction (T2MI) in a cohort of patients presenting to the Emergency Department (ED) with chest pain.

Methods This was a post hoc analysis of data collected from two prospective studies. Data were collected between November 2008 and February 2011 for the first study, and between February 2011 and March 2014 for the second. Participants were patients presenting to the ED with symptoms suggestive of acute coronary syndrome (ACS). The outcome was 30-day diagnosis; classified into T1MI, T2MI or non-MI. Descriptive statistics were used to compare the demographics, clinical history and presenting symptoms across diagnoses (T1MI, T2MI and non-MI). Cumulative mortality over 1 year was compared for T1MI and T2MI.

Results 147 patients (6.3%; 95% CI 5.3% to 7.3%) were classified as T1MI and 52 (2.2%; 95% CI 1.7% to 2.9%) were classified as T2MI. T2MIs were more likely to be female (OR 4.71, 95% CI 2.28 to 9.76), have an abnormal but non-ischaemic ECG (OR 2.95, 95% CI 1.45 to 6.00), report prior hypertension (OR 2.83, 95% CI 1.35 to 6.12), have tachycardia (OR 9.26, 95% CI 3.08 to 30.77) and pain at rest (OR 3.04, 95% CI 1.28 to 8.02) compared with T1MI. One-year mortality was similar between T1MI and T2MI (9% and 14.6%, respectively, p=0.37).

Conclusions T2MIs comprised one quarter of all MIs diagnosed in the ED. Among patients presenting to the ED with symptoms of ACS, symptoms do not allow clinicians to reliably differentiate patients with T1MI and T2MI. Prior hypertension, tachycardia and abnormal non-ischaemic ECGs are seen more often in T2MI compared with T1MI. One-year mortality was substantial in patients with T1MI and T2MI, but low power precludes conclusions about mortality differences between groups.

Impact and interest:

18 citations in Scopus
15 citations in Web of Science®
Search Google Scholar™

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

ID Code: 197665
Item Type: Contribution to Journal (Journal Article)
Refereed: Yes
ORCID iD:
Greenslade, Jaimi H.orcid.org/0000-0002-6970-5573
Parsonage, Williamorcid.org/0000-0002-0223-5378
Measurements or Duration: 7 pages
Keywords: acute myocardial infarction
DOI: 10.1136/emermed-2017-206869
ISSN: 1472-0205
Pure ID: 46538563
Divisions: Past > QUT Faculties & Divisions > Faculty of Health
Past > Institutes > Institute of Health and Biomedical Innovation
Funding Information: Funding The study has been supported by a grant from the Emergency Medicine Foundation, who played no role in the design and conduct of the study, the study analyses, the drafting and editing of the manuscript or its final content. Competing interests CM has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, Abbott, Alere, Astra Zeneca, Biomerieux, Beckman Coulter, Brahms, Nanosphere, Roche, Siemens, Singulex, Sphingotec, 8sense, Nanosphere, and the Department of Internal Medicine, University Hospital Basel, as well as speaker/consulting honoraria from Abbott, Alere, Astra Zeneca, Biomerieux, BG Medicine, BMS, Brahms, Cardiorentis, Daiichi Sankyo, Novartis, Radiometer, Roche, Sanofi, Siemens, and Singulex. WP is a consultant for Hospira/Pfizer outside the submitted work. LC reports grants from Roche and Beckmans; grants, consultancy fees, and personal fees from Abbott Diagnostics; grants and consultancy fess from Siemens; grants from Radiometer; personal fees from AstraZeneca; and personal fees from Novartis outside of the submitted work.
Copyright Owner: the Author(s)
Copyright Statement: This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au
Deposited On: 17 Mar 2020 03:46
Last Modified: 02 Mar 2024 07:40